Top Health Tech Companies in Belfast (25)
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
Benchling's Top Stability & Growth Strengths
Innovation-Driven Growth: New AI-focused capabilities (e.g., AI Connectors built on Model Context Protocol) and a stated push to be an “AI platform for biotech R&D” signal ongoing product investment. Reported usage of Benchling AI across 500 biotech companies underscores adoption of these innovations.
Strategic Partnerships: The January 2026 collaboration with Lilly’s TuneLab is positioned to bring proprietary models to scientists across Benchling’s customer base. Acqui-hires of ReSync Bio and Sphinx Bio in 2025 were used to accelerate the AI roadmap.
Strong Revenue Growth: ARR was independently estimated around the low-$200 millions by mid-2024 with year-over-year increases, indicating continued top-line expansion. While the pace has moderated versus earlier years, the trajectory remains positive.
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology, and the passion and creativity of our teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter...
Beckman Coulter Diagnostics's Top Stability & Growth Strengths
Strong Market Position & Advantage: Beckman Coulter Diagnostics is widely recognized as a leader in core‑lab IVD with broad adoption of its chemistry, immunoassay, and automation platforms, supported by Danaher’s top‑tier diagnostics portfolio. Multiple analyses place Danaher (including Beckman) among the leading global diagnostics groups, underscoring substantial installed base and reach.
Innovation-Driven Growth: Recent FDA clearances (e.g., DxC 500i, NT‑proBNP on DxI 9000), Breakthrough Device designation for an Alzheimer’s blood test, and expansion of the DxI 9000 assay menu (including neurodegenerative markers) demonstrate an active pipeline. Research‑use‑only biomarker assays and ongoing menu additions further support platform adoption and reagent pull‑through.
Resilient & Sustainable Growth: Management highlighted mid‑single‑digit growth through 2025, with multiple consecutive quarters of mid‑single‑digit or better growth outside China and expectations for gradual end‑market improvement into 2026. The IVD and clinical chemistry analyzer markets are expanding, providing supportive demand tailwinds.
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Viatris's Top Stability & Growth Strengths
Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.
Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.
Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. We are 340,000 colleagues in two distinct and complementary businesses working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences. Optum delivers care aided by technology and data,...
UnitedHealth Group's Top Stability & Growth Strengths
Strong Market Position & Advantage: Rankings on the 2026 Fortune 500 and Global 500 reflect industry-leading revenue scale. AM Best identifies the company as the largest public insurer in the U.S./Canada, with Optum Rx among the "Big 3" PBMs.
Diversified Revenue Streams: A vertically integrated model spans UnitedHealthcare and Optum (Health, Insight, Rx), combining insurance, care delivery, pharmacy benefits, and analytics. This breadth supports performance across funding cycles and care settings.
Strong Revenue Growth: Consolidated revenue rose to about $447.6 billion in 2025 from $400.3 billion in 2024, and 2026 has delivered consecutive quarters around $112 billion while full-year earnings guidance was raised.
Healthcare is complex enough, finding the knowledge you need shouldn’t be. Eolas Medical is a knowledge management platform for clinicians, enabling instant access to information at the point of care. The platform is used by NHS Trusts, clinical teams, and individuals to support the delivery of patient care by consolidating and organising medical knowledge from trusted sources into a simple, easy-to-use...
AesthetiDocs combines Online Bookings & Documentation providing everything you need to run your whole clinic. Take your Aesthetic Clinic to the next level with AesthetiDocs bespoke booking and documentation application. Bookings, reminders, consent, documentation, prescriptions, aftercare photographs and payments can be managed by yourself or your clinic staff depending on your needs. A simple way to ensure you’re doing everything correctly to run...
ResMed provides medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
ResMed's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.
Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.
Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.
10,000 people, one global focus - enhancing the health and well-being of pets, people, and livestock. We are passionate about what we do at IDEXX – and why wouldn’t we be? When you’re working to raise the standard of care for pets, make drinking water safe for billions and keep our livestock population around the globe healthy and free of...
IDEXX's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double‑digit top‑line increases in 2025 and early 2026, with Q1 and Q2 2026 up 14% and 10% reported, respectively, and full‑year 2026 revenue guidance raised. Growth is broad‑based across Companion Animal Group diagnostics, Water, and LPD.
Profitability: Margin expansion is attributed to recurring diagnostics volume, pricing, and productivity, translating into higher EPS and operating leverage. Guidance and quarterly updates highlight continued earnings growth if these drivers are maintained.
Strong Market Position & Advantage: The company is widely regarded as the category leader in companion‑animal diagnostics, reinforced by an integrated ecosystem of instruments, consumables, labs, imaging, and software. Independent analyses consistently place it at or near the top across key diagnostics segments, supporting durable advantage.
The world needs to train 18 million more healthcare professionals by 2030. At MedAll we’re on a mission to solve this healthcare crisis by making great healthcare training more accessible to every healthcare professional, everywhere. Read more about our mission at MedAll.org/mission
Lantum is a workforce management platform that makes it easier for healthcare providers to mobilise their workforce, and for clinicians to work more flexibly. Our Connected Scheduling platform gives you a staff bank, rota tool and a clinician network all in one place to improve fill rates, cut admin time, and reduce costs. We started life as Network Locum in...
We constantly hear how healthcare systems are under pressure or broken and that healthcare is mired in siloed systems. But what if the visible cracks in healthcare were actually symptoms of not embracing the digital transformation other industries have used to flourish? Not giving our frontline heroes the tools required to do their job? What if we reimagined how care...
At Elanco, we work to improve the health of animals through innovative products and services for pets and farm animals around the world. As a global animal health company, we provide solutions that empower our customers to advance a vision of Food and Companionship Enriching Life. Since 1954, Elanco has committed to empowering veterinarians, farmers, and all those who care...
Elanco's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is growing year over year with acceleration in the latest quarter, and guidance indicates continued organic expansion into 2026.
Innovation-Driven Growth: Innovation revenue surpassed targets and management raised the next-year goal, supported by new launches such as Befrena, Credelio Quattro, Zenrelia, AdTab, and Experior.
Future-Ready Strategy: A multi‑year plan calls for ongoing organic growth and improving earnings metrics, underpinned by a late‑stage pipeline expected to deliver multiple potential blockbusters through 2026–2031.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 20,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology,...
Henry Schein's Top Stability & Growth Strengths
Strong Market Position & Advantage: Regulators, company filings, and independent coverage characterize Henry Schein as a top full‑service dental distributor with global scale and Fortune 500 standing. Its role in an FTC‑recognized oligopoly and breadth across distribution and software reinforce durable competitive advantages.
Resilient & Sustainable Growth: Recent results indicate steady year‑over‑year increases in sales and EPS, and management has reaffirmed guidance for modest top‑line and EBITDA growth. Share repurchases and a multi‑year operating‑income improvement program support a measured compounding profile.
Future-Ready Strategy: The company is investing in higher‑growth technology and value‑added services and pursuing AI‑enabled initiatives alongside a defined multi‑year operating plan. Portfolio moves in software, digital solutions, and specialty offerings are positioned to create switching costs and embed workflows in practices.
Welcome! We are Northern Ireland’s Premier Private Healthcare Group. Our mission is to become a world-class provider of healthcare solutions by putting our patients to the forefront of everything we do. Our aim is to make the Kingsbridge Healthcare Group the preferred choice for both patients and healthcare professionals. Because Life Matters. Companies within the Kingsbridge Healthcare Group include: Kingsbridge...
ESO is a fast-paced, growing data, technology, and research company passionate about improving community health and safety through the power of data. We pioneer innovative, user-friendly software to meet the changing needs of today’s EMS agencies, fire departments, and hospitals. We’re small enough to be nimble and fun, but big enough to be a great place to work. We serve...
ESO's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is positioned as an industry leader in EMS/fire software with broad adoption across agencies and hospitals, supported by a large data footprint and visibility in public-sector deployments.
Investor Backing & Capital Strength: Strategic investment backing from Vista Equity Partners (and references to other PE support) is presented as enabling accelerated investment in customer experience and technical innovation.
Innovation-Driven Growth: The product suite highlights differentiated interoperability and analytics capabilities (e.g., HDE, standards transitions, indices/research outputs) and continued feature releases and platform expansion that align with ongoing growth signals.
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com. Together with...
Stryker's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double-digit annual sales expansion through 2025, with management guiding to continued organic growth into 2026.
Strong Market Position & Advantage: Evidence highlights leadership in orthopedic robotics and top-tier standings among global medtech peers, with notable share in joint replacement and integrated OR technologies.
Diversified Revenue Streams: Multiple segments and recent vascular-focused acquisitions broaden growth drivers and reduce reliance on any single category.
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
Data Mastery is a data consultancy based in the Belfast and Dublin, helping organisations transform how they collect, model, and leverage data. We specialise in designing and delivering modern analytics solutions built on Azure, Microsoft Fabric and Power BI, enabling business users to make confident, data-informed decisions. Our approach is deeply consultative: we embed ourselves within client teams to understand business...
Affidea is a pan-European diagnostic imaging and community-based polyclinic and specialist healthcare services provider, operating in Greece since 2005 to offer high-quality, integrated primary health services.
